NASC Can B Corp
Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1509957 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (2023Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.8%
TTM net income YoY34.8%
TTM EPS YoY81.6%
Revenue 3-yr CAGR8.0%
Net income 3-yr CAGR—
Margins
Gross margin16.6%
Operating margin-347.3%
Net margin-451.7%
FCF margin-61.2%
EBITDA margin-282.9%
Returns
ROE-2,317.5%
ROA-75.8%
ROIC (approx.)-1,613.4%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets118.3%
Debt / equity—
Current ratio0.45x
Interest coverage-2.98x
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-65.7%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.16M | $6.69M | $4.60M | $1.71M | $2.31M |
| Cost of revenue | $1.80M | $4.07M | $1.61M | $278,062 | $598,584 |
| Gross profit | $358,698 | $2.61M | $2.99M | $1.43M | $1.71M |
| R&D expense | — | — | — | $165,000 | $150,000 |
| SG&A expense | — | $926,696 | $675,310 | — | — |
| Operating income | -$7.49M | -$14.17M | -$10.27M | -$7.54M | -$5.89M |
| Interest expense | $2.51M | $902,130 | $2.10M | $934,683 | $8,793 |
| Pretax income | -$9.73M | -$14.92M | -$12.17M | -$8.88M | -$5.90M |
| Income tax | $9,596 | $793 | $1,075 | $3,304 | $2,084 |
| Net income | -$9.74M | -$14.92M | -$12.17M | -$8.88M | -$5.90M |
| EBITDA | -$6.10M | -$12.76M | -$9.77M | -$7.41M | -$5.88M |
| EPS (basic) | -0.77 | -4.18 | -9.06 | -37.68 | -2.87 |
| EPS (diluted) | -0.77 | -4.18 | -9.06 | -37.68 | -2.20 |
| Weighted avg. shares (diluted) | 12.59M | 3.57M | 1.34M | 235,649 | 2.69M |
| Balance sheet | |||||
| Cash & equivalents | $34,006 | $73,194 | $449,001 | $457,798 | $46,540 |
| Receivables | $3.72M | $6.59M | $3.65M | $2.00M | $1.25M |
| Inventory | $1.62M | $2.02M | $2.55M | $344,954 | $784,497 |
| Current assets | $5.38M | $8.70M | $6.65M | $2.82M | $3.39M |
| PP&E, net | $4.11M | $5.43M | $7.05M | $994,979 | $1.08M |
| Goodwill | — | — | — | $55,849 | $55,849 |
| Intangibles | $95,144 | $107,144 | $369,015 | $523,009 | $1.34M |
| Total assets | $10.13M | $15.56M | $16.47M | $3.91M | $7.21M |
| Current liabilities | $11.98M | $12.42M | $9.46M | $2.23M | $505,668 |
| Total liabilities | $11.98M | $12.86M | $10.86M | $2.44M | $564,666 |
| Shareholders' equity | -$1.86M | $2.70M | $5.62M | $1.48M | $6.65M |
| Shares outstanding | 32.75M | 2.83M | 2.83M | 369,639 | 2.68M |
| Cash flow statement | |||||
| Operating cash flow | -$1.30M | -$3.95M | -$7.47M | -$1.95M | -$2.41M |
| Capital expenditure | $15,000 | — | $538,763 | $50,219 | $1.11M |
| Free cash flow | -$1.32M | — | -$8.01M | -$2.00M | -$3.52M |
| Investing cash flow | -$84,631 | — | -$716,293 | -$25,249 | -$1.66M |
| Financing cash flow | $1.35M | $3.57M | $8.17M | $2.38M | $3.31M |
| Depreciation & amortization | $1.39M | $1.41M | $493,656 | $124,388 | $12,627 |
| Stock-based compensation | $1.45M | $5.06M | $2.40M | $2.58M | $4.40M |
| Share buybacks | — | — | — | $560,000 | — |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.